BioSpace News Archive

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”) today announced results from a preclinical in vivo study for its highly selective CDK9 inhibitor, GFH009, that demonstrate robust inhibition of tumor growth in a mouse xenograft model of small cell lung cancer (SCLC).

Blue Water Vaccines Inc. (“BWV” or “Blue Water Vaccines” or the “Company”), today announced that Ali Fattom, Ph.D., will present at the World Vaccine & Immunotherapy Congress West Coast 2022 in San Diego, California on Thursday, December 1, 2022.

Compass Therapeutics, Inc. today announced that the first patient has been dosed in the Phase 1b study of CTX-471 in combination with KEYTRUDA®, Merck’s anti-PD-1 therapy, in patients with advanced solid tumors.

Neuvivo today announced the publication of a peer-reviewed paper titled: “Macrophage Targeted Sodium Chlorite (NP001) Slows Progression of ALS through Regulation of Microbial Translocation”.

Theralink Technologies today announced the acceptance of two poster presentations evaluating the potential use and utility of its novel RPPA (Reverse Phase Protein Array) technology at the San Antonio Breast Cancer Symposium (SABCS) 2022.

NeoDynamics AB today announced the appointment of current board member Matt Colpoys as head of the company’s US subsidiary.

Seagen to Highlight ADCETRIS ® (brentuximab vedotin) Clinical Progress at the 2022 American Society of Hematology (ASH) Annual Meeting.

India Globalization Capital, Inc. (NYSE American: IGC) (“IGC” or the “Company”), announced that it has begun “A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Trial of the Safety and Efficacy of IGC-AD1 on Agitation in Participants with Dementia due to Alzheimer’s Disease”.

Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women’s health and the treatment of female stress urinary incontinence (SUI), today announced the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11511110 covering Viveve’s treatment to address SUI in women.

Eloxx Pharmaceuticals, Inc. today announced that its Board of Directors has approved a 1-for-40 reverse stock split of the Company’s common stock.